Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-019 monotherapy or in combination with anti-PD-1 in advanced malignancies
CTR20220168Phase 2Completed
- Sponsor
- Leads Biolabs
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LBL-019 in Non-hematologic malignancy, hematopoietic malignancies, sponsored by Leads Biolabs. Started Feb 2022; status: completed.
02
Drugs
LBL-019
03
Conditions
Non-hematologic malignancyhematopoietic malignancies
Beyond the preview
Go deeper on CTR20220168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220168.